Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. / Modvig, S; Hallböök, H; Madsen, H.O.; Siitonen, S; Rosthøj, S; Tierens, A; Juvonen, V; Osnes, L T N; Vålerhaugen, H; Hultdin, M; Matuzeviciene, R; Stoskus, M; Marincevic, M; Lilleorg, A; Ehinger, M; Norén-Nystrøm, U; Toft, N.; Taskinen, M; Jónsson, O G; Pruunsild, K; Vaitkeviciene, G; Vettenranta, K; Lund, B.; Abrahamsson, J; Porwit, A; Schmiegelow, K.; Marquart, H. V.

In: Leukemia, Vol. 35, 2021, p. 1894–1906.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Modvig, S, Hallböök, H, Madsen, HO, Siitonen, S, Rosthøj, S, Tierens, A, Juvonen, V, Osnes, LTN, Vålerhaugen, H, Hultdin, M, Matuzeviciene, R, Stoskus, M, Marincevic, M, Lilleorg, A, Ehinger, M, Norén-Nystrøm, U, Toft, N, Taskinen, M, Jónsson, OG, Pruunsild, K, Vaitkeviciene, G, Vettenranta, K, Lund, B, Abrahamsson, J, Porwit, A, Schmiegelow, K & Marquart, HV 2021, 'Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting', Leukemia, vol. 35, pp. 1894–1906. https://doi.org/10.1038/s41375-020-01100-5

APA

Modvig, S., Hallböök, H., Madsen, H. O., Siitonen, S., Rosthøj, S., Tierens, A., Juvonen, V., Osnes, L. T. N., Vålerhaugen, H., Hultdin, M., Matuzeviciene, R., Stoskus, M., Marincevic, M., Lilleorg, A., Ehinger, M., Norén-Nystrøm, U., Toft, N., Taskinen, M., Jónsson, O. G., ... Marquart, H. V. (2021). Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. Leukemia, 35, 1894–1906. https://doi.org/10.1038/s41375-020-01100-5

Vancouver

Modvig S, Hallböök H, Madsen HO, Siitonen S, Rosthøj S, Tierens A et al. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. Leukemia. 2021;35:1894–1906. https://doi.org/10.1038/s41375-020-01100-5

Author

Modvig, S ; Hallböök, H ; Madsen, H.O. ; Siitonen, S ; Rosthøj, S ; Tierens, A ; Juvonen, V ; Osnes, L T N ; Vålerhaugen, H ; Hultdin, M ; Matuzeviciene, R ; Stoskus, M ; Marincevic, M ; Lilleorg, A ; Ehinger, M ; Norén-Nystrøm, U ; Toft, N. ; Taskinen, M ; Jónsson, O G ; Pruunsild, K ; Vaitkeviciene, G ; Vettenranta, K ; Lund, B. ; Abrahamsson, J ; Porwit, A ; Schmiegelow, K. ; Marquart, H. V. / Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. In: Leukemia. 2021 ; Vol. 35. pp. 1894–1906.

Bibtex

@article{7aa51ad0c7dd404294406034e825393b,
title = "Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting",
abstract = "PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p < 0.0001), 29 (HzR 2.7, p < 0.0001), and 79 (HzR 3.5, p < 0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4 × 10-2 versus 5.2 × 10-3, p < 0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y = 3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD > 10-4 associated with a CIR5y = 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.",
author = "S Modvig and H Hallb{\"o}{\"o}k and H.O. Madsen and S Siitonen and S Rosth{\o}j and A Tierens and V Juvonen and Osnes, {L T N} and H V{\aa}lerhaugen and M Hultdin and R Matuzeviciene and M Stoskus and M Marincevic and A Lilleorg and M Ehinger and U Nor{\'e}n-Nystr{\o}m and N. Toft and M Taskinen and J{\'o}nsson, {O G} and K Pruunsild and G Vaitkeviciene and K Vettenranta and B. Lund and J Abrahamsson and A Porwit and K. Schmiegelow and Marquart, {H. V.}",
year = "2021",
doi = "10.1038/s41375-020-01100-5",
language = "English",
volume = "35",
pages = "1894–1906",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

AU - Modvig, S

AU - Hallböök, H

AU - Madsen, H.O.

AU - Siitonen, S

AU - Rosthøj, S

AU - Tierens, A

AU - Juvonen, V

AU - Osnes, L T N

AU - Vålerhaugen, H

AU - Hultdin, M

AU - Matuzeviciene, R

AU - Stoskus, M

AU - Marincevic, M

AU - Lilleorg, A

AU - Ehinger, M

AU - Norén-Nystrøm, U

AU - Toft, N.

AU - Taskinen, M

AU - Jónsson, O G

AU - Pruunsild, K

AU - Vaitkeviciene, G

AU - Vettenranta, K

AU - Lund, B.

AU - Abrahamsson, J

AU - Porwit, A

AU - Schmiegelow, K.

AU - Marquart, H. V.

PY - 2021

Y1 - 2021

N2 - PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p < 0.0001), 29 (HzR 2.7, p < 0.0001), and 79 (HzR 3.5, p < 0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4 × 10-2 versus 5.2 × 10-3, p < 0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y = 3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD > 10-4 associated with a CIR5y = 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.

AB - PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p < 0.0001), 29 (HzR 2.7, p < 0.0001), and 79 (HzR 3.5, p < 0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4 × 10-2 versus 5.2 × 10-3, p < 0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y = 3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD > 10-4 associated with a CIR5y = 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.

U2 - 10.1038/s41375-020-01100-5

DO - 10.1038/s41375-020-01100-5

M3 - Journal article

C2 - 33318611

VL - 35

SP - 1894

EP - 1906

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -

ID: 253349937